Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1940260 | 0.87 | KDR (0.49) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL1943078 | 0.86 | KDR (0.46) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL1942182 | 0.86 | KDR (0.43) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL1942594 | 0.84 | KDR (0.46) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL1941128 | 0.84 | KDR (0.48) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL1942005 | 0.83 | KDR (0.47) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL1940883 | 0.83 | KDR (0.47) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL1941819 | 0.83 | KDR (0.46) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL1940225 | 0.82 | PTPN11 (0.45) | KDRSMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL1940003 | 0.81 | KDR (0.42) | KDRSMN1; SMN2TP53ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717229-B1 | NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN | SANTEN PHARMACEUTICAL CO LTD (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1717229-A1 | NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | KDR 12/4885SMN1; SMN2 4412/4885TP53 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.